Percent who made changes to medical drugs because of cost in the past year
Measure Overview
The cost of medical drugs in the United States is significantly higher than in other nations. Rising medical drug prices in recent years have made it difficult for some Americans to afford their prescriptions. As a result, individuals may alter their medical drug consumption behavior out of financial necessity, such as asking their doctor for cheaper medications, delaying refills, taking less medication than prescribed, skipping dosages, using alternative therapies, or buying medications out of the country. Measuring changes in medical drug consumption behavior is an important consideration when assessing health care affordability in the U.S.
State Health Compare provides annual, state-level rates of individuals who made changes to their medical drugs in the past 12 months due to cost. These rates are available across three different breakdowns: year, type of health insurance (private, public, or uninsured), and age group (either 19-64 years or 65 and older).
Generate customized graphics using this data by selecting one of the options below.
Related Product

A State-level Measure of Drug Affordability on State Health Compare: Made Changes to Medical Drugs Because of Cost
In 2016 Americans spent more on prescription medications per capita than residents of any other nation due to higher U.S. drug prices. This blog uses 2016 National Health Interview Survey estimates to analyze state variation in cost-related drug changes by age group, coverage type. State Health Compare is the only source of state-level estimates for this measure.

Employer-Sponsored Insurance (2019-2021): A National-Level Look at Cost and Coverage Rates (Infographic)
In this infographic, SHADAC researchers use 2021 data from the Medical Expenditure Panel Survey-Insurance Component (MEPS-IC) to analyze the private-sector ESI landscape both on the state-level and nationally. In order to understand the effects of the pandemic, we compare 2021 ESI access data against pre-pandemic (2019) estimates and 2021 ESI cost data against 2020 estimates.